Elimination of lymphatic filariasis as a public health problem in Malawi

Chiphwanya, John, Mkwanda, Square, Kabuluzi, Storn, Mzilahowa, Themba, Ngwira, Bagrey, Matipula, Dorothy E, Chaponda, Limbikani, Ndhlova, Paul, Katchika, Prince, Mahebere Chirambo, Chawananga, Moses, Philemon, Kumala, Justin, Chiumia, Martin, Barrett, Carrie, Betts, Hannah, Fahy, Joan, Rebollo Polo, Maria, Reimer, Lisa ORCID: https://orcid.org/0000-0002-9711-4981, Stanton, Michelle ORCID: https://orcid.org/0000-0002-1754-4894, Thomas, Brent ORCID: https://orcid.org/0000-0003-1118-5429, Freer, Sian, Molyneux, David ORCID: https://orcid.org/0000-0001-8537-7947, Bockarie, Moses, Mackenzie, Charles, Taylor, Mark ORCID: https://orcid.org/0000-0003-3396-9275, Martindale, Sarah and Kelly-Hope, Louise ORCID: https://orcid.org/0000-0002-3330-7629 (2024) 'Elimination of lymphatic filariasis as a public health problem in Malawi'. PLoS Neglected Tropical Diseases, Vol 18, Issue 2, e0011957.

Preview

Text journal.pntd.0011957.pdf - Accepted Version Available under License Creative Commons Attribution. Download (5MB) | Preview

Abstract

Lymphatic filariasis (LF) is a parasitic disease transmitted by mosquitoes, causing severe pain, disfiguring, and disabling clinical conditions such as lymphoedema and hydrocoele. LF is a global public health problem affecting 72 countries, primarily in Africa and Asia. Since 2000, the World Health Organization (WHO) has led the Global Programme to Eliminate Lymphatic Filariasis (GPELF) to support all endemic regions. This paper focuses on the achievements of the Malawi LF Elimination Programme between 2000 and 2020 to eliminate LF as a public health problem, making it the second sub-Saharan country to receive validation from the WHO. The Malawi LF Programme addressed the widespread prevalence of LF infection and disease across the country, using the recommended WHO GPELF strategies and operational research initiatives in collaboration with key national and international partners. First, to stop the spread of infection (i.e., interrupt transmission) and reduce the circulating filarial antigen prevalence from as high as 74.4% to below the critical threshold of 1-2% prevalence, mass drug administration (MDA) using a two-drug regime was implemented at high coverage rates (>65%) of the total population, with supplementary interventions from other programmes (e.g., malaria vector control). The decline in prevalence was monitored and confirmed over time using several impact assessment and post-treatment surveillance tools including the standard sentinel site, spot check, and transmission assessment surveys and alternative integrated, hotspot, and easy-access group surveys. Second, to alleviate suffering of the affected populations (i.e., control morbidity) the morbidity management and disability prevention (MMDP) package of care was implemented. Specifically, clinical case estimates were obtained via house-to-house patient searching activities; health personnel and patients were trained in self-care protocols for lymphoedema and/or referrals to hospitals for hydrocoele surgery; and the readiness and quality of treatment and services were assessed with new survey tools. Malawi's elimination of LF will ensure that future generations are not infected and suffer from the disfiguring and disabling disease. However, it will be critical that the Malawi LF Elimination programme remains vigilant, focussing on post-elimination surveillance and MMDP implementation and integration into routine health systems to support long-term sustainability and ongoing success. Lymphatic filariasis, also known as elephantiasis, is a disabling, disfiguring, and painful disease caused by a parasite that infected mosquitoes transmit to millions of people worldwide. Since 2000, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) has supported endemic countries such as Malawi in south-eastern Africa, to eliminate the disease as a public health problem. The Malawi National LF Elimination Programme has worked tirelessly over the past two decades to implement the GPELF recommended strategies to interrupt the transmission with a two-drug regime, and to alleviate suffering in patients with lymphoedema and/or hydrocoele through morbidity management and disability prevention. Additionally, the LF Programme has collaborated with national and international stakeholders to implement a range of supplementary operational research projects to address outstanding knowledge gaps and programmatic barriers. In 2020, the World Health Organisation validated that Malawi had successfully eliminated LF as a public health problem, making it the second country in sub-Saharan Africa to achieve this, which is remarkable given that Malawi previously had very high infection rates. The LF Programme now remains vigilant, putting its efforts towards post-elimination surveillance and the continued implementation of care for patients with chronic conditions. Malawi's elimination of LF will ensure that future generations are not affected by this devastating disease.

Item Type:	Article
Subjects:	WC Communicable Diseases > Tropical and Parasitic Diseases > WC 880 Filariasis and related conditions (General) WH Hemic and Lymphatic Systems > Lymphatic System > WH 700 Lymphatic system. Lymphatic diseases (General)
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology Biological Sciences > Vector Biology Department
Digital Object Identifer (DOI):	https://doi.org/10.1371/journal.pntd.0011957
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	29 Feb 2024 11:11
Last Modified:	29 Feb 2024 11:11
URI:	https://archive.lstmed.ac.uk/id/eprint/24115

Statistics

View details

Actions (login required)

Edit Item